Antibody Specificity Testing Market Report: Market Size & Forecast 2026

Antibody specificity testing encompasses analytical methods and services that evaluate whether therapeutic antibodies bind exclusively to their intended targets, screening for off-target interactions that could compromise drug safety and efficacy. The global market reached approximately $0.93 billion in 2025 and is expanding steadily as biologics, including monoclonal antibodies and antibody-drug conjugates, dominate pharmaceutical development pipelines.

• •Market valued at $0.93 billion globally in 2025
• •Projected CAGR of 7.3% through the forecast period
• •Critical for ensuring developability and regulatory approval of therapeutic antibodies

The expansion of antibody-drug conjugate programs has intensified demand for rigorous specificity testing, as these therapeutics require precise target validation to minimize off-target toxicity. Advances in machine learning and protein language models are enabling earlier detection of non-specific binding during preclinical development, reducing costly late-stage failures.

• •Rapid growth in antibody-drug conjugate pipeline with double-digit annual expansion
• •Integration of machine learning and biophysical parameters for early-stage non-specificity prediction
• •Pharmaceutical industry adoption of predictive toxicity and specificity screening models such as organ-on-chip platforms

The market spans diverse technology platforms including immunoassays, surface plasmon resonance, bio-layer interferometry, and emerging microfluidic organ-on-chip systems. Geographically, North America and Europe currently dominate due to established biopharmaceutical infrastructure, while the Asia-Pacific region is accelerating rapidly driven by China's expanding R&D capabilities and synthetic biology investments.

• •Key technologies include immunoassays, biophysical interaction analysis, and microfluidic platforms
• •Asia-Pacific emerging as high-growth region supported by China's pharmaceutical R&D expansion
• •Point-of-care infectious disease diagnostics creating additional demand for antibody specificity validation

What are the recent trends and outlook?

The convergence of artificial intelligence with biophysical testing is reshaping antibody specificity workflows, with protein language models increasingly used to predict non-specific interactions before laboratory confirmation. Regulatory agencies are placing greater emphasis on comprehensive specificity data for biologics approvals, supporting sustained market expansion.

• •AI and protein language models emerging as complementary tools for predicting antibody non-specificity early in development
• •Regulatory scrutiny of antibody specificity and developability parameters intensifying globally
• •Continued double-digit growth in targeted antibody platforms including PD-(L)1 inhibitors expected to sustain demand through 2030